{"protocolSection": {"identificationModule": {"nctId": "NCT02918071", "orgStudyIdInfo": {"id": "D3250C00031"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home", "officialTitle": "A Multicenter, Open-Label, Functionality, Reliability and Performance Study of a Single-Use Auto-Injector With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GRECO)", "acronym": "GRECO"}, "statusModule": {"statusVerifiedDate": "2018-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-11-10", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-08-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-08-21", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-09-27", "studyFirstSubmitQcDate": "2016-09-27", "studyFirstPostDateStruct": {"date": "2016-09-28", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-08-01", "resultsFirstSubmitQcDate": "2018-10-30", "resultsFirstPostDateStruct": {"date": "2018-11-02", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-10-30", "lastUpdatePostDateStruct": {"date": "2018-11-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to assess functionality, performance, and reliability of an single-use auto-injector (AI) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver, and to confirm the safety and clinical benefit of benralizumab administration in asthma patients with severe asthma"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma,", "Bronchial Diseases,", "Respiratory Tract Diseases,", "Lung Diseases,", "Obstructive Lung Diseases,", "Benralizumab"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 121, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm Benralizumab", "type": "EXPERIMENTAL", "description": "Benralizumab administered subcutaneously every 4 weeks", "interventionNames": ["Biological: Benralizumab"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Benralizumab", "description": "Benralizumab administered subcutaneously every 4 weeks", "armGroupLabels": ["Arm Benralizumab"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an AI Device at Home", "description": "Patients who are still in the study is defined as patients who had been treated for the specified timepoint. A successful administration is defined as an injection completed, an answer of \"Yes\" to all 5 questions in the Questionnaire, and adequately passed the visual inspection and function tests.", "timeFrame": "Week 12, Week 16, Week 12 and 16"}, {"measure": "Number of Returned AI Devices Used to Administer Benralizumab at Home That Have Been Evaluated as Functional", "description": "AI evaluated as functional is defined as the device having adequately passed the visual inspection and function tests.", "timeFrame": "Week 12, Week 16"}, {"measure": "Number of AI Devices Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints)", "description": "Number (%) of AI used to administer benralizumab at home or in the clinic and have been reported as malfunctioning (Product Complaints). The percentage is calculated based on AI dispensed for patients who were treated for the specific time point. This excludes AIs dispensed but never used for the treatment or the device not returned for evaluation.", "timeFrame": "Weeks 0, 4, 8, 12, 16, 0 to 8, 12 to 16, and 0 to 16"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Asthma Control Questionnaire-6 (ACQ-6) Score", "description": "The effect of benralizumab on asthma control metrics in terms of change from baseline in mean Asthma Control Questionnaire-6 (ACQ-6) score. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations, and rescue medication. Baseline is defined as the last non-missing observation prior to the first dose of study treatment. ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Smaller score indicates better controlled asthma.", "timeFrame": "Week 0 (baseline) and weeks 4, 8, 12, 16, 20"}, {"measure": "The Pharmacokinetics (PK) of Benralizumab in the Terms of PK Parameters: Serum Concentration of Benralizumab", "description": "Mean PK Concentration at each visit", "timeFrame": "Baseline, Week 8, Week 20, and Week 28"}, {"measure": "The Pharmacodynamics of Benralizumab in the Terms of Peripheral Blood Eosinophil Levels", "description": "Blood eosinophil counts by timepoint", "timeFrame": "Baseline, Week 20, and Week 28"}, {"measure": "The Immunogenicity of Benralizumab in the Terms of Anti-drug Antibodies (ADA)", "description": "Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \\>=2 post-baseline assessments (with \\>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive", "timeFrame": "Baseline until Week 28"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria\n\n* Written informed consent for study participation must be obtained prior to any study related procedures being performed and according to international guidelines and/or applicable European Union (EU) guidelines\n* Male and female patients aged 18 to 75 years of age at the time of Visit 1\n* Patient or caregiver must be willing and able to self-administer the Investigational product (IP). Caregiver must be age of consent or older at the time of Visit 1, if applicable\n* Weight of \u226540 kg\n* Evidence of asthma as documented by airway reversibility (FEV1 \u226512% and 200 ml) demonstrated at Visit 1 or 1A or Visit 2\n* Documented history of current treatment with Inhaled corticosteroids (ICS) and Long-acting \u03b22 agonists (LABA). The ICS and LABA can be parts of a combination product or given by separate inhalers. The ICS dose must be greater than or equal to 500 \u03bcg/day fluticasone propionate dry powder formulation or equivalent daily. For ICS/LABA combination preparations, both the mid- and high-strength maintenance doses approved in the local country will meet this ICS criterion. Additional asthma controller medications (e.g., Leukotriene receptor antagonists (LTRAs), tiotropium, theophylline, oral corticosteroids) are allowed\n* Pre-bronchodilator (pre-BD) FEV1 of \\>50% predicted normal at Visit 1 or 1A or Visit 2\n* Not well controlled asthma as documented by either: An Asthma Control Questionnaire 6 (ACQ6 ) \u22651.5 OR; A peak flow of 60-80% predicted OR; One or more exacerbation that required oral or systemic corticosteroids in the previous year\n\nExclusion criteria:\n\n* Clinically important pulmonary disease other than asthma (eg, active lung infection, COPD (Chronic obstructive pulmonary disease), bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome)\n* Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could: Affect the safety of the patient throughout the study; Influence the findings of the studies or their interpretations; Impede the patient's ability to complete the entire duration of study\n* Known history of allergy or reaction to the IP formulation\n* History of anaphylaxis to any biologic therapy\n* History of Guillain-Barr\u00e9 syndrome\n* A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to standard of care therapy\n* Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening\n* Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Gary T. Ferguson, MD, PC", "affiliation": "Pulmonary Research Institute of Southeast Michigan", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Northridge", "state": "California", "zip": "91324", "country": "United States", "geoPoint": {"lat": 34.22834, "lon": -118.53675}}, {"facility": "Research Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Research Site", "city": "Westminster", "state": "California", "zip": "92683", "country": "United States", "geoPoint": {"lat": 33.75918, "lon": -118.00673}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33126", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Winter Park", "state": "Florida", "zip": "32789-4681", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Research Site", "city": "Albany", "state": "Georgia", "zip": "31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "Research Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Research Site", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "Research Site", "city": "Edmond", "state": "Oklahoma", "zip": "73034", "country": "United States", "geoPoint": {"lat": 35.65283, "lon": -97.4781}}, {"facility": "Research Site", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Research Site", "city": "McKinney", "state": "Texas", "zip": "75071", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Research Site", "city": "Plano", "state": "Texas", "zip": "75093", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Sherwood Park", "state": "Alberta", "zip": "T8L 0N2", "country": "Canada", "geoPoint": {"lat": 53.51684, "lon": -113.3187}}, {"facility": "Research Site", "city": "Ajax", "state": "Ontario", "zip": "L1S 2J5", "country": "Canada", "geoPoint": {"lat": 43.85012, "lon": -79.03288}}, {"facility": "Research Site", "city": "Burlington", "state": "Ontario", "zip": "L7N 3V2", "country": "Canada", "geoPoint": {"lat": 43.38621, "lon": -79.83713}}, {"facility": "Research Site", "city": "Kanata", "state": "Ontario", "zip": "K2L 3C8", "country": "Canada", "geoPoint": {"lat": 45.3001, "lon": -75.91606}}, {"facility": "Research Site", "city": "Mississauga", "state": "Ontario", "zip": "L5A 3V4", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H3G 1L5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H4J 1C5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Quebec City", "state": "Quebec", "zip": "G1V 4W2", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Sherbrooke", "state": "Quebec", "zip": "J1H 5N4", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -71.89908}}, {"facility": "Research Site", "city": "Trois-Rivi\u00e8res", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1G 3Y8", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Related Info", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4092&filename=d3250c00031-csp-v-1_REDACTED.pdf"}, {"label": "Related Info", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4092&filename=d3250c00031-sap-ed-2_REDACTED.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "121 participants receive treatment with benralizumab 30 mg at every 4 weeks schedule.", "groups": [{"id": "FG000", "title": "Benra 30 mg", "description": "Benralizumab administered subcutaneously every 4 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "121"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "118"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Benra 30 mg", "description": "Benralizumab administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "121"}]}], "measures": [{"title": "Age, Continuous", "populationDescription": "Full analysis set", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "48.5", "spread": "14.95"}]}]}]}, {"title": "Sex: Female, Male", "populationDescription": "Full analysis set", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "77"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "44"}]}]}]}, {"title": "Race/Ethnicity, Customized", "populationDescription": "Full analysis set", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "97"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an AI Device at Home", "description": "Patients who are still in the study is defined as patients who had been treated for the specified timepoint. A successful administration is defined as an injection completed, an answer of \"Yes\" to all 5 questions in the Questionnaire, and adequately passed the visual inspection and function tests.", "populationDescription": "Full analysis set - all patients who were administered for at least one dose of Benralizumab.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Week 12, Week 16, Week 12 and 16", "groups": [{"id": "OG000", "title": "Benra 30mg", "description": "Benralizumab administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "113"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "112"}]}]}, {"title": "Week 12 and 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "108"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-pearson Exact CI", "statisticalComment": "One sample Confidence Interval (Week 12)", "paramType": "percentage", "paramValue": "97.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "92.63", "ciUpperLimit": "99.46", "estimateComment": "Percentage of patients successfully administered benralizumab with an AI at home (Week 12)"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-pearson Exact CI", "statisticalComment": "One sample Confidence Interval (Week 16)", "paramType": "Percentage", "paramValue": "96.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "91.41", "ciUpperLimit": "99.05", "estimateComment": "Percentage of patients who successfully administered benralizumab with an AI at home (Week 16)"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-pearson Exact CI", "statisticalComment": "One sample Confidence Interval (Week 12 and 16)", "paramType": "Percentage", "paramValue": "93.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "86.86", "ciUpperLimit": "96.98", "estimateComment": "Percentage of patients who successfully administered benralizumab with an AI at home (Week 12 and 16)"}]}, {"type": "PRIMARY", "title": "Number of Returned AI Devices Used to Administer Benralizumab at Home That Have Been Evaluated as Functional", "description": "AI evaluated as functional is defined as the device having adequately passed the visual inspection and function tests.", "populationDescription": "Full analysis set - all patients who were administered for at least one dose of Benralizumab.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_UNITS", "unitOfMeasure": "Auto-injector", "timeFrame": "Week 12, Week 16", "typeUnitsAnalyzed": "Auto-injector", "denomUnitsSelected": "Auto-injector", "groups": [{"id": "OG000", "title": "Benra 30mg", "description": "Benralizumab administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}, {"units": "Auto-injector", "counts": [{"groupId": "OG000", "value": "234"}]}], "classes": [{"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}]}, {"units": "Auto-injector", "counts": [{"groupId": "OG000", "value": "117"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "114"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}]}, {"units": "Auto-injector", "counts": [{"groupId": "OG000", "value": "117"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "113"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-pearson Exact CI", "statisticalComment": "One sample Confidence Interval (Week 12)", "paramType": "Percentage", "paramValue": "97.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "92.69", "ciUpperLimit": "99.47", "estimateComment": "Percentage of patients returned functional AI administered at home (Week 12)"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper Pearson Exact CI", "statisticalComment": "One sample confidence interval (Week 16)", "paramType": "Percentage", "paramValue": "96.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "91.48", "ciUpperLimit": "99.06", "estimateComment": "Percentage of patients returned functional AI administered at home (Week 16)"}]}, {"type": "PRIMARY", "title": "Number of AI Devices Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints)", "description": "Number (%) of AI used to administer benralizumab at home or in the clinic and have been reported as malfunctioning (Product Complaints). The percentage is calculated based on AI dispensed for patients who were treated for the specific time point. This excludes AIs dispensed but never used for the treatment or the device not returned for evaluation.", "populationDescription": "Number of Units analyzed per row represents number of auto-injector used at each time point.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_UNITS", "unitOfMeasure": "Auto-injector", "timeFrame": "Weeks 0, 4, 8, 12, 16, 0 to 8, 12 to 16, and 0 to 16", "typeUnitsAnalyzed": "Auto-injector", "denomUnitsSelected": "Auto-injector", "groups": [{"id": "OG000", "title": "Benra 30mg", "description": "Benralizumab administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}, {"units": "Auto-injector", "counts": [{"groupId": "OG000", "value": "595"}]}], "classes": [{"title": "Week 0", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}, {"units": "Auto-injector", "counts": [{"groupId": "OG000", "value": "121"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}, {"units": "Auto-injector", "counts": [{"groupId": "OG000", "value": "121"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}, {"units": "Auto-injector", "counts": [{"groupId": "OG000", "value": "119"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}, {"units": "Auto-injector", "counts": [{"groupId": "OG000", "value": "117"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}, {"units": "Auto-injector", "counts": [{"groupId": "OG000", "value": "117"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Week 0 to Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}, {"units": "Auto-injector", "counts": [{"groupId": "OG000", "value": "361"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Week 12 to Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}, {"units": "Auto-injector", "counts": [{"groupId": "OG000", "value": "234"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}]}]}, {"title": "Week 0 to Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}, {"units": "Auto-injector", "counts": [{"groupId": "OG000", "value": "595"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-pearson Exact CI", "statisticalComment": "One sample Confidence Interval (Week 0)", "paramType": "Percentage", "paramValue": "0.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.00", "ciUpperLimit": "3.00", "estimateComment": "Percentage of mulfunctioning AI used to administer benralizumab at home or clinic (Week 0)"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-pearson Exact CI", "statisticalComment": "One sample Confidence Interval (Week 4)", "paramType": "Percentage", "paramValue": "0.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.02", "ciUpperLimit": "4.52", "estimateComment": "Percentage of malfunctioning AI used to administer benralizumab at home or clinic (Week 4)"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-pearson Exact CI", "statisticalComment": "One sample Confidence Interval (Week 8)", "paramType": "Percentage", "paramValue": "0.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.02", "ciUpperLimit": "4.59", "estimateComment": "Percentage of malfunctioning AI used to administer benralizumab at home or clinic (Week 8)"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-pearson Exact CI", "statisticalComment": "One sample Confidence Interval (Week 12)", "paramType": "Percentage", "paramValue": "2.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.53", "ciUpperLimit": "7.31", "estimateComment": "Percentage of malfunctioning AI used to administer benralizumab at home or clinic (Week 12)"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-pearson Exact CI", "statisticalComment": "One sample Confidence Interval (Week 16)", "paramType": "Percentage", "paramValue": "3.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.94", "ciUpperLimit": "8.52", "estimateComment": "Percentage of malfunctioning AI used to administer benralizumab at home or clinic (Week 16)"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-pearson Exact CI", "statisticalComment": "One sample Confidence Interval (Week 0 to 8)", "paramType": "Percentage", "paramValue": "0.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.07", "ciUpperLimit": "1.99", "estimateComment": "Percentage of malfunctioning AI used to administer benralizumab at home or clinic (Week 0 to 8)"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-pearson Exact CI", "statisticalComment": "One sample Confidence Interval (Week 12 to 16)", "paramType": "Percentage", "paramValue": "3.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.21", "ciUpperLimit": "6.07", "estimateComment": "Percentage of malfunctioning AI used to administer benralizumab at home or clinic (Week 12 to 16)"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Clopper-pearson Exact CI", "statisticalComment": "One sample Confidence Interval (Week 0 to 16)", "paramType": "Percentage", "paramValue": "1.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.69", "ciUpperLimit": "2.85", "estimateComment": "Percentage of malfunctioning AI used to administer benralizumab at home or clinic (Week 0 to 16)"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Asthma Control Questionnaire-6 (ACQ-6) Score", "description": "The effect of benralizumab on asthma control metrics in terms of change from baseline in mean Asthma Control Questionnaire-6 (ACQ-6) score. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations, and rescue medication. Baseline is defined as the last non-missing observation prior to the first dose of study treatment. ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Smaller score indicates better controlled asthma.", "populationDescription": "Full analysis set - all patients who were administered for at least one dose of Benralizumab.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Week 0 (baseline) and weeks 4, 8, 12, 16, 20", "groups": [{"id": "OG000", "title": "Benra 30mg", "description": "Benralizumab administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.63", "spread": "0.99"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.91", "spread": "1.05"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "117"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.07", "spread": "1.02"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.13", "spread": "1.06"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.04", "spread": "1.08"}]}]}]}, {"type": "SECONDARY", "title": "The Pharmacokinetics (PK) of Benralizumab in the Terms of PK Parameters: Serum Concentration of Benralizumab", "description": "Mean PK Concentration at each visit", "populationDescription": "PK analysis set - include all patients who had at least one quantifiable serum PK observation post first dose of Benralizumab.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline, Week 8, Week 20, and Week 28", "groups": [{"id": "OG000", "title": "Benra 30mg", "description": "Benralizumab administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Value is less than lower limit of quantification"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "118"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "698.18", "spread": "186.455"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "787.51", "spread": "280.788"}]}]}, {"title": "Week 28", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "117"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "62.86", "spread": "469.359"}]}]}]}, {"type": "SECONDARY", "title": "The Pharmacodynamics of Benralizumab in the Terms of Peripheral Blood Eosinophil Levels", "description": "Blood eosinophil counts by timepoint", "populationDescription": "Full analysis set - all patients who were administered for at least one dose of Benralizumab.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "cells/ uL", "timeFrame": "Baseline, Week 20, and Week 28", "groups": [{"id": "OG000", "title": "Benra 30mg", "description": "Benralizumab administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "230", "lowerLimit": "150", "upperLimit": "360"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "118"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20", "lowerLimit": "10", "upperLimit": "30"}]}]}, {"title": "Week 28", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20", "lowerLimit": "10", "upperLimit": "50"}]}]}]}, {"type": "SECONDARY", "title": "The Immunogenicity of Benralizumab in the Terms of Anti-drug Antibodies (ADA)", "description": "Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \\>=2 post-baseline assessments (with \\>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive", "populationDescription": "Full analysis set - all patients who were administered for at least one dose of Benralizumab.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline until Week 28", "groups": [{"id": "OG000", "title": "Benra 30mg", "description": "Benralizumab administered subcutaneously every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}], "classes": [{"title": "Positive at any visit", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}, {"title": "Base- and Post-baseline Positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Only post-baseline positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}, {"title": "Only baseline positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Persistently Positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}]}]}, {"title": "Transiently Positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "28 weeks.", "description": "Adverse events were collected from the time the patient signed the informed consent, throughout the treatment period and including the follow-up period (through Week 28).\n\nSerious adverse events were recorded from the time of informed consent.", "eventGroups": [{"id": "EG000", "title": "Benra 30 mg", "description": "Benralizumab administered subcutaneously every 4 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 121, "seriousNumAffected": 1, "seriousNumAtRisk": 121, "otherNumAffected": 45, "otherNumAtRisk": 121}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 121}]}], "otherEvents": [{"term": "Seasonal allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 121}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 121}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 121}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 10, "numAtRisk": 121}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 22, "numAffected": 18, "numAtRisk": 121}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 121}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 10, "numAtRisk": 121}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "\u2265 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation."}, "pointOfContact": {"title": "Ubaldo Martin, Global Clinical Lead Benralizumab", "organization": "AstraZeneca", "email": "Ubaldo.Martin@astrazeneca.com", "phone": "+1 301 398 0163"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2016-08-23", "uploadDate": "2018-09-18T07:19", "filename": "Prot_000.pdf", "size": 1022123}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-09-25", "uploadDate": "2018-09-18T07:20", "filename": "SAP_001.pdf", "size": 2915492}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571386", "term": "Benralizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M287399", "name": "Benralizumab", "asFound": "Aorta", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}